Abstract:e13631 Background: The emergence of novel therapeutic targets, targeted drugs, and immune checkpoint inhibitors has catalyzed a paradigm shift from single-target testing to comprehensive genomic profiling in the treatment of solid tumors. However, the tangible benefits of this shift in terms of treatment optimization and patient prognosis improvement have yet to be fully substantiated. Methods: In this retrospective study, we analyzed genomic data from 1032 patients with solid tumors to identify actionable genetic alterations, calculate tumor mutation burden (TMB), measure PD-L1 expression via immunohistochemistry, and assess microsatellite instability (MSI) status. These assessments were utilized to evaluate potential therapeutic targets and immunotherapy-related markers for each patient. Results: Between January 2018 and July 2020, 1032 patients underwent genomic profiling, received treatment, and were followed up. Of 1156 treatment episodes, 423 involved targeted monotherapy or combination therapy, 114 involved immune checkpoint inhibitor therapy, and 619 involved chemotherapy or anti-angiogenic therapy. Patients receiving matched therapy (n=491) demonstrated significantly higher partial response rates (31.7% vs 10.4%, P<0.001) and longer median progression-free survival (PFS) (159 days vs 96 days, P<0.001) compared to those receiving unmatched therapy (n=665). Based on the highest level of mutation carried, there were 475, 8, 153, 405, and 115 patients with grade I, II, III, IV, and V alterations, respectively. Among patients with grade I-II alterations, 65.63% received targeted therapy, resulting in significantly longer PFS compared to those undergoing immunotherapy or chemotherapy (200 days vs 109 days vs 94 days). Conversely, only 16.8% of patients with grade III-IV alterations received targeted treatment, with marginal PFS improvement (112 days vs 114 days vs 92 days). Notably, an increase in the number of actionable variants was associated with a significant decrease in PFS among patients receiving targeted therapy. However, the number of actionable variants did not significantly affect PFS in patients receiving chemotherapy or immunotherapy. Within our cohort, 44 patients with cancer of unknown primary (CUP) underwent molecular diagnostic evaluation, leading to the reclassification of 32 patients based on their molecular profiles. Notably, 24 patients harbored actionable genetic variants, 9 patients had a high TMB (≥10 Muts/Mb), and 3 patients exhibited high PD-L1 expression (TPS ≥50%). Conclusions: Comprehensive genomic profiling demonstrates clinical utility in guiding treatment decisions and improving prognosis for patients with advanced solid tumors. These findings advocate for the integration of next-generation sequencing into the therapeutic regimens for these malignancies.

Impact of Comprehensive Genome Profiling on the Management of Advanced Non-Small Cell Lung Cancer: Preliminary Results From the Lung Cancer Cohort of the FPG500 Program

Molecular Characterization and Prognostic Analysis of Non-Small Cell Lung Cancer: A Single Centric Real-World Study.

Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer

Real-world performance and clinical outcome of comprehensive genomic profiling of gastrointestinal tumors: High-volume, single-center experience.

Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study

Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1

Mutational Landscape of Cfdna Identifies Distinct Molecular Features Associated with Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC.

Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker screening in daily clinical practice

Clinical Applications of Comprehensive Genomic Profiling in Advanced Non-Small-Cell Lung Cancer—A Case Series

Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors

Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials

Case report: Single gene testing and comprehensive genomic profiling in non-small cell lung cancer—a case series of divergent results from a large reference laboratory

Combined Focused Next-Generation Sequencing Assays to Guide Precision Oncology in Solid Tumors: A Retrospective Analysis from an Institutional Molecular Tumor Board

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

The Introduction of Systematic Genomic Testing for Patients with Non-Small Cell Lung Cancer (nsclc) at Dana-Farber Cancer Institute (Dfci)

Comprehensive genomic profiling in solid tumors: Enhancing treatment selection and prognosis.

Clinical utility of Next Generation Sequencing of plasma cell-free DNA for the molecular profiling of patients with NSCLC at diagnosis and disease progression

Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling

Implementing precision oncology for sarcoma patients: the CCCLMUmolecular tumor board experience

Use of Comprehensive Genomic Profiling for Biomarker Discovery for the Management of Non-Small Cell Lung Cancer Brain Metastases

Molecular and Genomic Profiling of Lung Cancer in the Era of Precision Medicine: A Position Paper from the Italian Association of Thoracic Oncology (AIOT)